PDDPF News and Press, Medexus Pharmaceuticals Inc From 08/21/20

MONTREAL, Aug. 21, 2020 (GLOBE NEWSWIRE) -- Medexus Pharmaceuticals Inc.  (the “Company” or “Medexus”) (TSXV: MDP, OTCQX: MEDXF; PDDPF) today announces that it has begun trading on the OTCQX ® Best Market under the new ticker “MEDXF,” e...

Medexus Pharmaceuticals ( OTCQX:PDDPF ) : Q1 Net loss of C$4.8M vs. C$2.2M in year ago quarter. More news on: Medexus Pharmaceuticals Inc., Earnings news and commentary, Healthcare stocks news, , Read more ...

Strong organic growth across all key product lines, including recently acquired IXINITY ® Generated $4.1 million of cash flow from operations Management to host conference call at 8:00 AM ET on Wednesday, August 12, 2020 TORONTO, CHICAGO and MONTREAL, Aug. 11, 2020 (GLOBE...

MONTREAL, Aug. 11, 2020 (GLOBE NEWSWIRE) -- Medexus Pharmaceuticals Inc. (the “Company” or “Medexus”) (TSXV: MDP, OTCQX: PDDPF) today announced that it will be presenting at the Canaccord Genuity 40 th Annual Growth Conference being held virtually on August 11...

MONTREAL, Aug. 05, 2020 (GLOBE NEWSWIRE) -- Medexus Pharmaceuticals Inc. (the “Company” or “Medexus”) (TSXV: MDP, OTCQX: PDDPF) today announced that it plans to host a conference call at 8:00 AM Eastern Time on Wednesday, August 12, 2020 to discuss the Company&...

NEW YORK , Aug. 4, 2020 /PRNewswire/ -- OTC Markets Group Inc.  (OTCQX: OTCM), operator of financial markets for 10,000 U.S. and global securities, today announced Medexus Pharmaceuticals Inc. (TSX-V: MDP;  OTCQX: PDDPF), a commercial-stage specialty pharmaceutical c...

Medexus Pharmaceuticals ( OTCQB:PDDPF )  announced that Triamcinolone Hexacetonide Injectable Suspension 20 mg/mL (TH) has been approved for inclusion on the Alberta Drug Benefit List (ADBL), the Saskatchewan Drug Plan, Newfoundland and Labrador Prescription Drug Program (NLPDP) a...

MONTREAL, July 09, 2020 (GLOBE NEWSWIRE) -- Medexus Pharmaceuticals Inc.  (the “Company” or “Medexus”) (TSXV: MDP, OTCQB: PDDPF) is pleased to announce that Triamcinolone Hexacetonide Injectable Suspension 20 mg/mL (TH) has been approved for inclusion on t...

Transformative acquisition of IXINITY® completed February 28, 2020 Fiscal 2020 Metoject® unit market demand increased 96%; Rupall™ unit market demand increased 61%; and Rasuvo® unit market demand increased 11% Medexus management to host conference call a...

MONTREAL, June 17, 2020 (GLOBE NEWSWIRE) -- Medexus Pharmaceuticals Inc. (the “Company” or “Medexus”) (TSXV: MDP, OTCQB: PDDPF) today announced that it plans to host a conference call at 8:00 AM Eastern Time on Tuesday, June 23, 2020 to discuss the Company ...